Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 4, 2016, Pages 586-590

  Robinson, Jennifer G ^a   Ray, Kausik ^b  

^a UNIVERSITY OF IOWA   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

atherosclerosis; cholesterol; goals; LDL cholesterol; patient preference

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CORONARY ARTERY ATHEROSCLEROSIS; ELECTRIC POTENTIAL; HUMAN; ISCHEMIC HEART DISEASE; LOW RISK PATIENT; NOTE; PATIENT PREFERENCE; PRIORITY JOURNAL; RISK REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPLICATION; DECISION SUPPORT SYSTEM; DYSLIPIDEMIAS; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84961219042     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.306887     Document Type: Note

References (23)

1. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239. doi: 10.1161/01. CIR.0000133317.49796.0E.
3. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 pt B):2889-2934. doi: 10.1016/j.jacc.2013.11.002.
4. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a.
5. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64:485-494. doi: 10.1016/j. jacc.2014.02.615.
6. Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe Added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397. doi: 10.1056/NEJMoa1410489.
7. Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499. doi: 10.1056/ NEJMoa1501031.
8. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-1509. doi: 10.1056/NEJMoa1500858.
9. Puri R, Nissen SE, Shao M, Uno K, Kataoka Y, Kapadia SR, Tuzcu EM, Nicholls SJ. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. Am J Cardiol. 2014;114:1465-1472. doi: 10.1016/j. amjcard.2014.08.009.
10. Robinson JG, Stone NJ. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J. 2015;36:2110-2118. doi: 10.1093/eurheartj/ehv182.
11. Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. Eur Heart J. 2015;36:2975-2983. doi: 10.1093/eurheartj/ehv340.
12. Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey; 2000;320:1446-1447.
13. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
14. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220-1226. doi: 10.2337/ dc05-2465.
15. Sanofi/Regeneron. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727). ClinicalTrials.gov Identifier: NCT01663402. 2015;April 3, 2015.
16. Amgen. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). ClinicalTrials.gov Identifier: NCT01764633. 2014;April 3, 2015.
17. Pfizer. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2).ClinicalTrials.gov Identifier: NCT01975389. 2015;April 3, 2015.
18. Pfizer. The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1). ClinicalTrials.gov Identifier: NCT01975376. 2015;April 3, 2015.
19. Study of the Effectiveness of Additional Reductions in Cholesterol Homocysteine Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658-1669.
20. de Lemos JA, Blazing MA, Wiviott SD, et al; Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316. doi: 10.1001/jama.292.11.1307.
21. The HPS2-THRIVE Collaborative Group. Effects of extendedrelease niacin with laropriprant in high-risk patients. N Engl J Med. 2014;371:203-2012.
22. The AIM-HIGH Investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med. 2011;365:2255-2267.
23. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.